BioDelivery announced the enrollment and dosing of the first patient in its Phase 3 program evaluating the efficacy and safety of BioErodible MucoAdhesive (BEMA) buprenorphine for the treatment of moderate-to-severe chronic pain. BioDelivery anticipates that positive findings from this study would then allow for an NDA filing in the first half of 2012.

BEMA Buprenorphine uses BioDelivery’s proprietary BEMA drug delivery technology, which consists of a small, dissolvable, polymer film for application to the buccal mucosa (inner lining of the cheek) to deliver the opioid analgesic buprenorphine.

For more information call (919) 582-9050 or visit